PE20040306A1 - Metodos terapeuticos de sapogeninas y sus derivados - Google Patents

Metodos terapeuticos de sapogeninas y sus derivados

Info

Publication number
PE20040306A1
PE20040306A1 PE2003000315A PE2003000315A PE20040306A1 PE 20040306 A1 PE20040306 A1 PE 20040306A1 PE 2003000315 A PE2003000315 A PE 2003000315A PE 2003000315 A PE2003000315 A PE 2003000315A PE 20040306 A1 PE20040306 A1 PE 20040306A1
Authority
PE
Peru
Prior art keywords
derivatives
therapeutic methods
sapogenins
cognitive
neurodegeneration
Prior art date
Application number
PE2003000315A
Other languages
English (en)
Inventor
Philip James Gunning
Yaer Hu
Daryl Rees
Zongqin Xia
Antonia Orsi
Original Assignee
Phytopharm Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ARP020101170A external-priority patent/AR033079A1/es
Application filed by Phytopharm Plc filed Critical Phytopharm Plc
Publication of PE20040306A1 publication Critical patent/PE20040306A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)

Abstract

SE REFIERE AL USO DE DERIVADOS DE SAPOGENINAS ESTEROIDEAS CON FORMULAS : I, II Y III, EN DONDE EL ATOMO DE CARBONO EN LA POSICION 3 O EN EL CASO DE LAS FORMULAS II O III, EL CARBONO EN LA POSICION 3, EN LA POSICION 26 O CADA UNO DE LOS CARBONO EN LAS POSICION 3 O 26, PORTA UNA POSICION DE O-AZUCAR QUE ES MONO, DI- O TRI-SACARIDOS, CARACTERIZADAS PORQUE LA SAPOGENINA PRECURSORA, LA CUAL ES SUSTITUIDA AL MENOS CON UN RADICAL X QUE CONSISTE EN HALOGENO, (Me-S-), Me-SO-), (Me-SO2), N3-, NH2-, MeSO2NH-, ALQUILO; SE SELECCIONA DE SARSASAPOGENINA, ESPISARSASAPOGENINA, ESMILAGENINA, EPISMILAGENINA, Y ANZUROGENINA-D Y SUS SALES DE CATILATO, SUCCINATO, GLICINATOS, ALINATOS, VALINATOS, ENTRE OTROS.TAMBIEN SE REFIERE AL USO DE ESTOS DERIVADOS EN UNA COMPOSICION FARMACEUTICA, PRODUCTOS ALIMENTICIOS, SUPLEMENTOS ALIMENTICIOS Y BEBIDAS, ADEMAS PUEDE ESTAR PRESENTE OTRO AGENTE ACTIVO ADICIONAL COMO INHIBIDORES DE COLINESTERASA, AGONISTAS DE DOPAMINA, INHIBIDORES DE COMT, INHIBIDORES DE LA MAO-B, ANTICOLINERGICOS, ENTRE OTROS; LOS COMPUESTOS SON UTILES EN EL TRATAMIENTO O PREVENCION DE i) NEURODEGENERACION NO COGNOCITIVA, ii)DEGENERACION NEUROMUSCULAR NO COGNOCITIVA, iii) NEURODEGENERACION MOTORA-SENSORIAL, iv) DISFUNCION O PERDIDA DEL RECEPTOR EN AUSCENCIA DE LA DEFICIENCIA COGNOCITIVA, NEURONAL Y NEUROMUSCULAR.
PE2003000315A 2002-03-27 2003-03-27 Metodos terapeuticos de sapogeninas y sus derivados PE20040306A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ARP020101170A AR033079A1 (es) 2001-03-28 2002-03-27 Derivados de sapogeninas, sintesis y uso, y metodos en base a su uso
US36817802P 2002-03-28 2002-03-28
PCT/GB2002/001578 WO2002079221A2 (en) 2001-03-28 2002-03-28 Sapogenin derivatives, their synthesis and use

Publications (1)

Publication Number Publication Date
PE20040306A1 true PE20040306A1 (es) 2004-05-29

Family

ID=30001210

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000315A PE20040306A1 (es) 2002-03-27 2003-03-27 Metodos terapeuticos de sapogeninas y sus derivados

Country Status (10)

Country Link
KR (1) KR20100093621A (es)
CN (1) CN1642558B (es)
AT (1) ATE424211T1 (es)
IL (1) IL164161A0 (es)
NZ (2) NZ547897A (es)
PE (1) PE20040306A1 (es)
PL (1) PL213697B1 (es)
RU (1) RU2332999C2 (es)
TW (1) TWI329016B (es)
WO (1) WO2003082893A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861788B2 (en) * 2003-06-03 2005-03-01 Motorola, Inc. Switchable display/mirror method and apparatus
FR2868700B1 (fr) * 2004-04-09 2008-09-26 Michel Coisy Utilisation de la dopamine ou de ses precurseurs biologiques contre l'algoneurodystrphie.
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
GB0424528D0 (en) 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
HUE035328T2 (en) 2005-10-28 2018-05-02 Univ Industry Cooperation Group Kyung Hee Univ Extract from Dioscoreaceae Family Plants and Composition Containing it for Prevention or Treatment of Peripheral Neuropathy
JP2012515754A (ja) 2009-01-24 2012-07-12 ファイトファーム ピーエルシー 神経栄養因子介在疾患の治療
CN103189056A (zh) * 2010-07-20 2013-07-03 植物药物公共有限公司 L-dopa、多巴胺激动剂和/或多巴胺增强剂诱导的紊乱的治疗
EP4245369A3 (en) 2011-09-08 2023-11-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CU20110244A7 (es) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
US11319338B2 (en) 2012-04-03 2022-05-03 Goldporp Pharma Limited Timosaponin compounds
CN112375115A (zh) 2013-03-13 2021-02-19 萨奇治疗股份有限公司 神经活性甾类化合物及其使用方法
CN103232520A (zh) * 2013-05-13 2013-08-07 中国药科大学 一种螺甾类化合物、其制备方法及医药用途
ES2970222T3 (es) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
BR112018000129B1 (pt) 2015-07-06 2024-01-09 Sage Therapeutics, Inc Compostos oxiesteróis, seus usos e composição farmacêutica
MA42409A (fr) 2015-07-06 2018-05-16 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
JP2018519328A (ja) 2015-07-06 2018-07-19 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
DK3436022T3 (da) 2016-04-01 2022-06-20 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse heraf
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3481846T3 (pl) 2016-07-07 2021-12-20 Sage Therapeutics, Inc. 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA
CN110023323A (zh) 2016-09-30 2019-07-16 萨奇治疗股份有限公司 C7取代的氧固醇及其作为nmda调节剂的方法
AU2017345399B2 (en) 2016-10-18 2022-02-24 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MX2019004578A (es) 2016-10-18 2019-10-09 Sage Therapeutics Inc Oxisteroles y metodos de uso de los mismos.
CN108264535A (zh) * 2016-12-30 2018-07-10 中国科学院上海药物研究所 一种抗抑郁化合物及其制备方法和应用
RU2635485C1 (ru) * 2017-03-21 2017-11-13 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения атрофии зрительного нерва после черепно-мозговой травмы
CN109988218B (zh) * 2017-12-29 2022-11-25 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用
EP3572085A1 (en) * 2018-05-25 2019-11-27 Neuro-Sys Synergestic combination composition comprising a steroidal saponin, a first polyphenolic compound and optionnaly a second polyphenolic compound
CN112457362B (zh) * 2019-09-06 2023-09-19 上海青东生物科技有限公司 一种卤代四环三萜衍生物及其制备与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3416112A1 (de) * 1984-04-30 1985-10-31 Roecar Holdings (Netherlands Antilles) N.V., Willemstad, Curacao, Niederländische Antillen Verwendung von sterolinen und spiroketalinen als lipoxygenaseregulatoren
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
JPH05246866A (ja) * 1992-03-06 1993-09-24 Ruibosuteii Japan:Kk 脳代謝促進・脳機能改善剤
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
TW479061B (en) * 1993-12-24 2002-03-11 Mitsubishi Chem Corp Sialic acid derivatives
JPH092957A (ja) * 1995-06-22 1997-01-07 Mitsubishi Chem Corp 末梢性神経障害の治療、予防薬
JPH092956A (ja) * 1995-06-22 1997-01-07 Mitsubishi Chem Corp 神経障害の治療、予防薬
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
CN1131237C (zh) * 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
BR9909109A (pt) * 1998-03-26 2000-12-12 Phytopharm Plc Usos de um ou mais dentre esmilagenina, prazerigenina, um astragalosìdeo, tigogenina, ruscogenina, hecogenina, de diogenina, de esmilagenina, anzurogenina d ou um astragalosìdeo e de um extrato de uma planta do gênero smilax, asparagus, anemarrhena, yucca ou agave, composição para o tratamento de uma condição distinguida por uma deficiência da função ou do número de receptores pós-sinápticos ligados a membrana, composição farmacêutica, e, processos para acentuar a função cognitiva em um humano ou animal não-humano e em um paciente que sofre de uma disfunção cognitiva relacionada com a idade, e para tratar uma condição distinguida por uma deficiência da função ou do número de receptores ligados a membrana em um tecido, órgão, tipo de célula ou organela
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
JP2002030096A (ja) * 2000-07-11 2002-01-29 Kyorin Pharmaceut Co Ltd 神経細胞突起再生剤及びその製造方法
EP1496913A4 (en) * 2002-03-15 2007-10-31 Samaritan Pharmaceuticals Inc NEUROPROTECTIVE PHARMACEUTICAL SPIROSTENOL COMPOSITIONS

Also Published As

Publication number Publication date
CN1642558A (zh) 2005-07-20
RU2332999C2 (ru) 2008-09-10
TWI329016B (en) 2010-08-21
PL213697B1 (pl) 2013-04-30
CN1642558B (zh) 2012-05-30
WO2003082893A2 (en) 2003-10-09
WO2003082893A3 (en) 2004-04-15
NZ547344A (en) 2007-11-30
WO2003082893A8 (en) 2003-12-31
RU2004130281A (ru) 2006-01-20
NZ547897A (en) 2008-02-29
IL164161A0 (en) 2005-12-18
TW200400042A (en) 2004-01-01
PL372941A1 (en) 2005-08-08
KR20100093621A (ko) 2010-08-25
ATE424211T1 (de) 2009-03-15

Similar Documents

Publication Publication Date Title
PE20040306A1 (es) Metodos terapeuticos de sapogeninas y sus derivados
TR200700134T1 (tr) Sapogenin türevleri, bunların sentezi ve kullanımı, bunların kullanım metotları.
HK1046912A1 (en) Substituted sapogenins and their use
HRP20080467A2 (en) 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
DK1719512T3 (da) Sarsasapogenin og smilagenin til behandling af cognitive dysfunktioner
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
EP2301625A3 (en) Compositions and methods for treating cognitive disorders
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
GB9923078D0 (en) Sapogenin derivatives and their use
WO2004007531A3 (en) Activated checkpoint therapy and methods of use thereof
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
HRP20041009A2 (en) Theraputic methods and uses of sapogenins and their derivatives
TW200833344A (en) Therapeutic methods and uses of sapogenins and their derivatives
UA85187C2 (en) 2-aminobenzoyl derivatives
BR0308788A (pt) Processos terapêuticos e usos de sapogeninas e seus derivados
MY134920A (en) 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
WO2004073631A3 (en) Combination therapy for the treatment of neoplasms

Legal Events

Date Code Title Description
FC Refusal